Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.42 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3976665 | 0.91 | NPC1 (0.40) | TDP1GABRA5GPBAR1GHSRKDM4E | |
| SCHEMBL3977190 | 0.91 | POLB (0.46) | TDP1KDM4EP2RY12POLBALOX15 | |
| SCHEMBL3973247 | 0.90 | GABRA5 (0.43) | TDP1GABRA5GPBAR1KDM4EP2RY12 | |
| SCHEMBL3977472 | 0.88 | GABRA5 (0.38) | GABRA5KDM4EP2RY12POLBALOX15 | |
| SCHEMBL3984576 | 0.86 | CACNA1F (0.41) | TDP1KDM4EP2RY12POLBALOX15 | |
| SCHEMBL3975866 | 0.85 | BACE1 (0.43) | GPBAR1KDM4ETSHR | |
| SCHEMBL3978253 | 0.83 | HPGD (0.41) | GABRA5GPBAR1KDM4EPOLBTSHR | |
| SCHEMBL3979619 | 0.82 | CACNA1F (0.40) | TDP1KDM4EP2RY12POLBALOX15 | |
| SCHEMBL3982811 | 0.82 | ATM (0.43) | TDP1KDM4EP2RY12POLBALOX15 | |
| SCHEMBL3977560 | 0.81 | P2RY12 (0.39) | TDP1GPBAR1KDM4EP2RY12POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538132-B2 | Isoxazolo derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1931661-B1 | ISOXAZOLO DERIVATIVES AS GABA A ALPHA5 INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-11-19 | — | — | EP | disclosed |
| US-20070066668-A1 | Isoxazolo derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066668-A1 | Isoxazolo derivatives | GABRA5, GABRA4, GABRA1 | TDP1 3070/4885GABRA5 1/4885GPBAR1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.